Assessing risk of disease progression in rheumatoid arthritis patients

US8058013B2 · kind B2 · utility

Assignee

• Roche Diagnostics Operations, Inc. · US

Inventors

• Johann Karl · Peißenberg, DE
• Veit Peter Grunert · Munich, DE
• Wolfgang Rollinger · Polling, DE
• Norbert Wild · Geretsried, DE

Key dates

• Filing date: Mar 27, 2009
• Grant date: Nov 15, 2011
• Expiry date: Mar 27, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/102
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention.